Dr. Mark Goldstein, MD
Claim this profileJEM Research Institute
Expert in Alzheimer's Disease
Studies Colorectal Cancer
28 reported clinical trials
45 drugs studied
Area of expertise
1Alzheimer's Disease
Global LeaderAPOE
APOE ε4 positive
ApoE positive
2Colorectal Cancer
Stage IV
Stage III
dMMR positive
Affiliated Hospitals
Clinical Trials Mark Goldstein, MD is currently running
ACR-368
for Ovarian Cancer
This trial tests a new drug, ACR-368, alone or with a small dose of another drug, gemcitabine, in patients whose cancers don't respond to standard treatments. A special test helps decide which treatment might work best for each patient. Gemcitabine has been used with other drugs for various cancers, including pancreatic, lung, ovarian, and breast cancers.
Recruiting1 award Phase 1 & 210 criteria
Donanemab
for Alzheimer's Disease
This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.
Recruiting1 award Phase 34 criteria
More about Mark Goldstein, MD
Clinical Trial Related4 years of experience running clinical trials · Led 28 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Mark Goldstein, MD has experience with
- Placebo
- Donanemab
- Aducanumab
- Tavapadon
- ALZ-801
- Nicotine Transdermal Patch
Breakdown of trials Mark Goldstein, MD has run
Alzheimer's Disease
Colorectal Cancer
Mild Cognitive Impairment
- A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)
- A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
- Nicotine Patch for Mild Cognitive Impairment
Cognitive Impairment
- A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)
- A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
- Nicotine Patch for Mild Cognitive Impairment
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mark Goldstein, MD specialize in?
Mark Goldstein, MD focuses on Alzheimer's Disease and Colorectal Cancer. In particular, much of their work with Alzheimer's Disease has involved APOE patients, or patients who are APOE ε4 positive.
Is Mark Goldstein, MD currently recruiting for clinical trials?
Yes, Mark Goldstein, MD is currently recruiting for 7 clinical trials in Atlantis Florida. If you're interested in participating, you should apply.
Are there any treatments that Mark Goldstein, MD has studied deeply?
Yes, Mark Goldstein, MD has studied treatments such as Placebo, Donanemab, Aducanumab.
What is the best way to schedule an appointment with Mark Goldstein, MD?
Apply for one of the trials that Mark Goldstein, MD is conducting.
What is the office address of Mark Goldstein, MD?
The office of Mark Goldstein, MD is located at: JEM Research Institute, Atlantis, Florida 33462 United States. This is the address for their practice at the JEM Research Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.